Search

Displaying results 181 - 190 of 151669 in total
  1. Drug

    AMG 424

    go.drugbank.com/drugs/DB17357
    Investigational

    AMG 424 is a novel, humanized, anti-CD3/CD38 bispecific monoclonal antibody being investigated for multiple myeloma.

    Synonyms: Humanized Bi-Specific Xmab(R) T Cell Recruiting Antibody Construct Directed Against Cd3 And Cd38
  2. Drug

    Anbenitamab

    go.drugbank.com/drugs/DB18411
    Investigational

    Synonyms: FC-fusion bispecific antibody targeting extracellular domains II and IV of HER 2 and FC-fusion bispecific IgG1 antibody inhibiting PD-L1 and CTLA-4
  3. Drug

    TN-401

    go.drugbank.com/drugs/DB18140
    Investigational

    TN-401 is a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human PKP2 gene.

    Synonyms: A native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human PKP2 gene
  4. Drug

    TN-201

    go.drugbank.com/drugs/DB18700
    Investigational

    TN-201 is a gene therapy comprising a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human MYBPC3 gene.

    Synonyms: Native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human MYBPC3 gene
  5. Drug

    Nendratareotide uzatansine

    go.drugbank.com/drugs/DB18351
    Investigational

    Nendratareotide uzatansine is a peptide-drug conjugate comprising a peptide analog of somatostatin conjugated to the cytotoxin mertansine.

    Synonyms: Peptide-drug conjugate combining [(Tyr3,Cys8) octreotate amide] and N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl) maytansine
  6. Drug

    Viagenpumatucel-L

    go.drugbank.com/drugs/DB16348
    Investigational

    Viagenpumatucel-L is under investigation in clinical trial NCT02117024 (A Phase 2 Study of Viagenpumatucel-l (HS-110) in Patients With Non-small Cell Lung Cancer).

    Synonyms: Gp96-igg1-fc fusion protein and hla-a1 expressing, irradiated ad-100 whole cell vaccine
  7. Drug

    TRK-001

    go.drugbank.com/drugs/DB18577
    Investigational

    TRK-001 is an autologous regulatory T-cell therapy. It is being investigated for the prevention of graft rejection following solid organ transplantation.

    Synonyms: Natural Regulatory T Cells (T-Regs), Expanded with Interleukin-2, ExpAct Beads (CD3/CD28; Miltenyi), Rapamycin and Transforming Growth Factor-beta
  8. Drug

    CLL1-CD33 compound chimeric antigen receptor T cells

    go.drugbank.com/drugs/DB18568
    Investigational

    Synonyms: Chimeric Antigen Receptor immunotherapy directed against CLL-1 and CD33
  9. Drug

    DT-DEC01

    go.drugbank.com/drugs/DB19433
    Experimental

    DT-DEC01 is a novel Dystrophin Expressing Chimeric (DEC) cell therapy being investigated by Dystrogen Therapeutics Corporation.

    Synonyms: Dystrophin Expressing Chimeric Cells derived from allogenic normal human myoblast and autologous DMD myoblast from Duchenne muscular dystrophy affected donor
  10. Drug

    Fepixnebart

    go.drugbank.com/drugs/DB19079
    Investigational

    Fepixnebart is under investigation in clinical trial NCT04456686 (Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis).

    Synonyms: Ly3016859 (humanized monoclonal antibody to human tgf.alpha. and epiregulin), IMMUNOGLOBULIN G4 (226-PROLINE,232-ALANINE,233-ALANINE,DE-C-TERMINAL-LYSINE), ANTI-(HUMAN EPIREGULIN AND TRANSFORMING GROWTH FACTOR .ALPHA.)